Generic Name and Formulations:
Tobramycin 0.3%, dexamethasone 0.1%; oph. susp; contains benzalkonium chloride.
Alcon Laboratories, Inc.
Indications for TOBRADEX:
Ocular inflammation associated with infection or risk thereof.
Adults and Children:
<2yrs: not recommended. ≥2yrs: 1–2 drops every 2hrs for 1st 24–48 hrs, then every 4–6 hrs. Reduce dose as condition improves; max 20mL for initial ℞.
Viral, fungal, or mycobacterial infections of the eye.
Corneal or scleral thinning. Glaucoma. Monitor for secondary infections, intraocular pressure and cataracts in prolonged use. Monitor blood levels in combined aminoglycoside therapy. Avoid abrupt cessation. Pregnancy (Cat.C). Nursing mothers.
Aminoglycoside + steroid.
Local effects (eg, eye pain, eyelids pruritus, eyelid edema, conjunctival hyperemia or erythema), increased intraocular pressure, glaucoma, cataracts, corneal perforations, optic nerve damage, delayed wound healing, secondary infection.
Susp—2.5mL, 5mL, 10mL; Oint—3.5g
Renal and Urology News Articles
- Gadolinium-Based Contrast May Up Acute Kidney Injury Risk in CKD
- Delayed Prostate Cancer Treatment May Up Relapse Risk
- Review: Desmopressin Decreases Nocturia Episodes
- Surgery, Radiation Regimens for High-Grade PCa Offer Similar Outcomes
- Salvage Prostatectomy May Benefit Some Prostate Cancer Patients
- Changes in Renal Cell Carcinoma Pathologic Staging and Histologic Grading
- Nocturia, Overactive Bladder Improved With PTNS
- Many Americans Unaware of Promise of Personalized Medicine
- Noninferior CV Outcomes for Linagliptin in T2D With High CV, Renal Risk
- VDRAs Do Not Lower Cardiovascular Event Risk in HD
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)